AMENDMENTS TO THE CLAIMS

1. (original) A pharmaceutical preparation to be dispersed before administration, comprising active granules comprising a pharmaceutically active substance and having an average particle diameter of 2 mm or less; and a thickening agent, wherein the pharmaceutical preparation is capable of being administered through an NG tube by dispersing in water before administration.

2. (original) The pharmaceutical preparation to be dispersed before administration according to claim 1, wherein the active granules further comprise a functional polymer.

3. (original) The pharmaceutical preparation to be dispersed before administration according to claim 2, wherein the functional polymer is at least one selected from the group consisting of gastric polymers, enteric polymers and sustained release polymers.

4. (original) The pharmaceutical preparation to be dispersed before administration according to any one of claims 1 to 3, wherein the thickening agent is at least one selected from the group consisting of propylene glycol alginate, methyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, sodium polycarboxymethyl cellulose and hydroxypropyl cellulose.

5. (currently amended) The pharmaceutical preparation to be dispersed before administration according to ~~any one of claims 1 to 4~~ claim 1, further comprising placebo granules containing no pharmaceutically active substance.

6. (currently amended) The pharmaceutical preparation to be dispersed before administration according to ~~any one of claims 1 to 5~~ claim 1, wherein the pharmaceutical preparation has a viscosity of 10 to 1500 mPa·s when dispersed in water before administration.

7. (currently amended) The pharmaceutical preparation to be dispersed before administration according to ~~any one of claims 1 to 6~~ claim 1, wherein the pharmaceutically active substance is a proton pump inhibitor.

8. (original) The pharmaceutical preparation to be dispersed before administration according to claim 7, wherein the proton pump inhibitor is at least one selected from the group consisting of rabeprazole, omeprazole, esomeprazole, lansoprazole and pantoprazole.